Many preclinical treatment strategies for stroke have failed when tested in human
trials. Although the reasons for these translation failures are multifactorial,
one potential concern is the statistical analysis of the preclinical data. One
way to rigorously evaluate new therapies is to use an intention-to-treat
analysis in preclinical studies. Therefore, in this study, we set out to
evaluate the treatment efficacy of a potential clinically relevant therapeutic
agent for stroke, i.e., anti-Nogo-A immunotherapy, using an intention-to-treat
analysis. Adult rats were trained on the skilled forelimb reaching task and
subsequently underwent an ischemic stroke. Nine weeks later, the rats either
received intracerebroventricular anti-Nogo-A antibody, control antibody, or no
treatment. Skilled reaching performance was assessed by a non-linear model using
both an intention-to-treat and per-protocol analysis. Following testing,
dendritic complexity was evaluated in the contralesional and perilesional
sensorimotor cortex. Both intention-to-treat and per-protocol analysis showed
that anti-Nogo-A immunotherapy resulted in statistically significant improved
recovery on the skilled forelimb reaching task, although treatment effect was
less (though statistically significant) in the intention-to-treat group.
Improved functional performance was not shown to be associated with dendritic
changes. In conclusion, this study provides evidence for the importance of using
intention-to-treat paradigms in testing preclinical therapeutic strategies.